nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2017-4-3-27-34nodgo-312Research ArticleОригинальные исследованияРезультаты лечения острого миелобластного лейкоза у младенцев в Республике БеларусьResults of treatment of acute myeloid leukemia in infants in BelarusАлейниковаО. В.AleynikovaO. V.

Республика Беларусь, 223053, Минская область, Минский район, Боровлянский с/с, д. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk district, Minsk region, 223053, Republic of Belarus

aleinikova2004@mail.ruБаровскаяЮ. А.BarovskayaYu. A.

Республика Беларусь, 223053, Минская область, Минский район, Боровлянский с/с, д. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk district, Minsk region, 223053, Republic of Belarus

ВасиленкоД. А.VasilenkoD. A.

Республика Беларусь, 220116, Минск, просп. Дзержинского, 83

83 Prosp. Dzerzhinskogo, Minsk, 220116, Republic of Belarus

БыдановО. И.BydanovO. I.

Республика Беларусь, 223053, Минская область, Минский район, Боровлянский с/с, д. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk district, Minsk region, 223053, Republic of Belarus

ГУ РНПЦ ДОГИ Министерства здравоохранения Республики БеларусьБеларусьRepublican Center for Pediatric Oncology, Hematology and ImmunologyBelarusУО «Белорусский государственный медицинский университет»БеларусьBelarusian State Medical UniversityBelarus201720092017432734Copyright © Алейникова О.В., Баровская Ю.А., Василенко Д.А., Быданов О.И., 20172017Алейникова О.В., Баровская Ю.А., Василенко Д.А., Быданов О.И.Aleynikova O.V., Barovskaya Y.A., Vasilenko D.A., Bydanov O.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/312

Статья посвящена анализу клинико-биологических характеристик и результатов лечения детей первого года жизни с острым миелоидным лейкозом. В ретроспективное исследование вошли 18 пациентов в возрасте до 1 года, получавших лечение в Ре- спубликанском научно-практическом центре детской онкологии, гематологии и иммунологии (Минск, Республика Беларусь). Вероятность долгосрочной общей выживаемости составила 33 ± 11 %; бессобытийной – 28 ± 11 %; кумулятивная частота смертей, обусловленных лечением, – 66,7 ± 11,7 %; кумулятивная частота возникновения рецидива – 5,6 ± 5,6 %. Сделаны выводы о необходимости возрастной коррекции доз цитарабина.

 

Article represents analysis of clinical and biological characteristics and results of treatment of children of first year of life with acute myeloid leukemia. Retrospective analysis included 18 patients under the first year of life received treatment in Republican research center of pediatric oncology, hematology and immunology (Minsk, Belarus Republic). Probability of long-term overall survival was 33 ± 11 %; event-free survival – 28 ± 11 %; cumulative frequency of deaths related to treatment – 66.7 ± 11.7 %; cumulative frequency of relapse – 5.6 ± 5.6 %. Conclusions on age-related correction of cytarabine required.

 

дети первого года жизниноворожденныеострый миелоидный лейкозлечениеchildren of the first year of lifenewbornsacute myeloid leukemiatreatmentReferencesMasetti R., Rondelli R., Fagioli F. et al. Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica 2014;99(8):e127–9. doi: 10.3324/haematol.2014.106526.Masetti R., Rondelli R., Fagioli F. et al. Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children. Haematologica 2014;99(8):e127–9. doi: 10.3324/haematol.2014.106526.Gibson B.E., Webb D.K., Howman A.J. et al.; United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 2011;155(3):366–76. doi: 10.1111/j.1365-2141.2011.08851.x.Gibson B.E., Webb D.K., Howman A.J. et al.; United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol 2011;155(3):366–76. doi: 10.1111/j.1365-2141.2011.08851.x.Rubnitz J.E., Inaba H., Dahl G. et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11(6):543–52. doi: 10.1016/S1470- 2045(10)70090-5.Rubnitz J.E., Inaba H., Dahl G. et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11(6):543–52. doi: 10.1016/S1470- 2045(10)70090-5.Cooper T.M., Franklin J., Gerbing R.B. et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer 2012;118(3):761–9. doi: 10.1002/cncr.26190.Cooper T.M., Franklin J., Gerbing R.B. et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer 2012;118(3):761–9. doi: 10.1002/cncr.26190.Abrahamsson J., Forestier E., Heldrup J. et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011;29(3):310–5. doi: 10.1200/ JCO.2010.30.6829.Abrahamsson J., Forestier E., Heldrup J. et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011;29(3):310–5. doi: 10.1200/ JCO.2010.30.6829.Цаур Г.А. Молекулярно-биологическая диагностика и мониторинг минимальной остаточной болезни в лечении острых лейкозов у детей первого года жизни. Автореф. дис. … д-ра мед. наук. Екатеринбург, 2015. [Tsaur G.A. Molecular-biological diagnostics and monitoring of minimal residual disease in the treatment of acute leukemia in children of the first year of life. Thesis abstract of … Ph. D. Med. Yekaterinburg, 2015. (In Russ.)].Цаур Г.А. Молекулярно-биологическая диагностика и мониторинг минимальной остаточной болезни в лечении острых лейкозов у детей первого года жизни. Автореф. дис. … д-ра мед. наук. Екатеринбург, 2015. [Tsaur G.A. Molecular-biological diagnostics and monitoring of minimal residual disease in the treatment of acute leukemia in children of the first year of life. Thesis abstract of … Ph. D. Med. Yekaterinburg, 2015. (In Russ.)].Creutzig U., Zimmermann M., Bourquin J.-P. et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012;26(4):654–61. doi: 10.1038/leu.2011.267.Creutzig U., Zimmermann M., Bourquin J.-P. et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012;26(4):654–61. doi: 10.1038/leu.2011.267.Andrade F.G., Noronha E.P., Brisson G.D. et al.; Brazilian Study Group of Childhood Acute Myeloid Leukemia (IMol-AMLBSG) as co-authors. Molecular Characterization of Pediatric Acute Myeloid Leukemia: Results of a Multicentric Study in Brazil. Arch Med Res 2016;47(8):656–67. doi: 10.1016/j.arcmed.2016.11.015.Andrade F.G., Noronha E.P., Brisson G.D. et al.; Brazilian Study Group of Childhood Acute Myeloid Leukemia (IMol-AMLBSG) as co-authors. Molecular Characterization of Pediatric Acute Myeloid Leukemia: Results of a Multicentric Study in Brazil. Arch Med Res 2016;47(8):656–67. doi: 10.1016/j.arcmed.2016.11.015.Løhmann J.A., Abrahamsson J., Ha S.Y. et al. Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. Haematologica 2016;101(11):1359–67. doi:Løhmann J.A., Abrahamsson J., Ha S.Y. et al. Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004. Haematologica 2016;101(11):1359–67. doi:3324/haematol.2016.146175 10. van Dongen J.J., Macintyre E.A., Gabert J.A. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13(12):1901–28. PMID: 10602411.3324/haematol.2016.146175 10. van Dongen J.J., Macintyre E.A., Gabert J.A. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13(12):1901–28. PMID: 10602411.Калинина И.И., Шнейдер М.М., Кирсанова Н.П. и др. Клинические и генетические особенности острого миелоидного лейкоза с t(8;21) у детей и результаты терапии по протоколу ОМЛ- ММ-2000. Онкогематология 2011;6(1):11–8. [Kalinina I.I., Shneyder M.M., Kirsanova N.P. et al. Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000. Onkogematologiya = Oncogematology 2011;6(1):11–8. (In Russ.)].Калинина И.И., Шнейдер М.М., Кирсанова Н.П. и др. Клинические и генетические особенности острого миелоидного лейкоза с t(8;21) у детей и результаты терапии по протоколу ОМЛ- ММ-2000. Онкогематология 2011;6(1):11–8. [Kalinina I.I., Shneyder M.M., Kirsanova N.P. et al. Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000. Onkogematologiya = Oncogematology 2011;6(1):11–8. (In Russ.)].Kaplan E., Meier P. Nonparametric Estimation from Incomplete Observations. J Am Statist Assoc 1958;53(282):457–81.Kaplan E., Meier P. Nonparametric Estimation from Incomplete Observations. J Am Statist Assoc 1958;53(282):457–81.Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18(6):695–706. PMID: 10204198.Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18(6):695–706. PMID: 10204198.Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16(3):1140–54.Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16(3):1140–54.Periclou A.P., Avramis V.I. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 1996;39(1–2):42–50. PMID: 8995498.Periclou A.P., Avramis V.I. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 1996;39(1–2):42–50. PMID: 8995498.

The authors declare that there are no conflicts of interest present.